Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical are making significant strides in the development of BH3120, a next-generation cancer immunotherapy. Updates on the innovative treatment were ... Read More
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More